BioArctic receives Orphan Drug Designation for exidavnemab the US
Go back to BioArctic receives Orphan Drug Designation for exidavnemab the US| BARNES GROUP, Inc. (NYSE: B) | Delayed: 40.23 +0.13 (0.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $40.10 | 52 Week High | $44.27 | |||
| Open | $40.65 | 52 Week Low | $30.07 | |||
| Day High | $40.73 | P/E | 30.71 | |||
| Day Low | $39.73 | EPS | $1.31 | |||
| Volume | 7,822,213 | |||||
| BIOAMBER, Inc. (NASDAQ: BIOA) | Delayed: 6.61 -0.2 (2.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.81 | 52 Week High | $8.73 | |||
| Open | $6.92 | 52 Week Low | $2.86 | |||
| Day High | $6.92 | P/E | N/A | |||
| Day Low | $6.47 | EPS | $-3.82 | |||
| Volume | 869,993 | |||||
